Real-world efficacy and safety of open-source automated insulin delivery for people with type 1 diabetes mellitus: Experience from mainland China
- 30 October 2024
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 218, 111910
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Automated Insulin Delivery for Young People with Type 1 Diabetes and Elevated A1cNEJM Evidence, 2024
- Asia-Pacific consensus recommendations for application of continuous glucose monitoring in diabetes managementDiabetes Research and Clinical Practice, 2023
- Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 DiabetesJAMA, 2023
- Barriers to uptake of Open-Source automated insulin delivery Systems: Analysis of socioeconomic factors and perceived challenges of adults with type 1 diabetes from the OPEN surveyDiabetes Research and Clinical Practice, 2022
- Continuous glucose monitoring and metrics for clinical trials: an international consensus statementThe Lancet Diabetes & Endocrinology, 2022
- Open-Source Automated Insulin Delivery in Type 1 DiabetesNew England Journal of Medicine, 2022
- Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 DiabetesNew England Journal of Medicine, 2022
- Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionalsThe Lancet Diabetes & Endocrinology, 2021
- Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control SystemDiabetes Technology & Therapeutics, 2021
- DIY artificial pancreas: A narrative of the first patient and the physicians’ experiences from IndiaDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021